Literature DB >> 33407648

Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results.

Dongha Lee1, Shohei Komatsu2, Kazuki Terashima3, Hirochika Toyama1, Yoshiro Matsuo3, Daiki Takahashi3, Masaki Suga4, Naoko Nishimura5, Kentaro Tai1, Masahiro Kido1, Yusuke Demizu3,6, Sunao Tokumaru3, Tomoaki Okimoto3, Ryohei Sasaki7, Takumi Fukumoto1.   

Abstract

BACKGROUND: Particle radiotherapy has increasingly gained acceptance for locally advanced pancreatic cancers owing to superior tumor conformity and dosimetry compared to conventional photon radiotherapy. However, the close proximity of the pancreas to the stomach and duodenum leads to radiation-induced gastrointestinal toxicities, which hinder the delivery of curative doses to the tumor. To overcome this problem, a surgical spacer was placed between the tumor and gastrointestinal tract, and subsequent proton radiotherapy was performed in this study.
METHODS: Data from 9 patients who underwent surgical spacer placement and subsequent proton radiotherapy were analyzed. The safety and feasibility of the spacer placement surgery were evaluated; the impact of the spacer on dosimetry was also assessed using dose volume histogram (DVH) analyses, before and after surgical spacer placement.
RESULTS: Surgical spacer placement and subsequent proton radiotherapy were successfully completed in all cases. Surgical spacer placement significantly improved the dose intensity covering 95%, mean, and minimum doses for the gross tumor volume, and the clinical and planning target volume based on the DVH, while respecting the dose constraints of the gastrointestinal tract. Based on the Common Terminology Criteria for Adverse Events, two patients (22.2%) developed gastrointestinal ulcer (Grade 2) at 1 and 35 months, and one patient (11.1%) developed gastric perforation (Grade 4) at 4 months after proton radiotherapy.
CONCLUSIONS: Surgical spacer placement in the locally advanced pancreatic body and tail cancers is relatively safe and technically feasible. Comparing radiation plans, surgical spacer placement seems to improve the dose distribution in the locally advanced pancreatic body and tail cancers, which are close to the gastrointestinal tract.

Entities:  

Keywords:  Dose volume histogram; Pancreatic cancer; Proton radiotherapy; Radiation toxicity; Surgical spacer

Year:  2021        PMID: 33407648     DOI: 10.1186/s13014-020-01731-z

Source DB:  PubMed          Journal:  Radiat Oncol        ISSN: 1748-717X            Impact factor:   3.481


  24 in total

Review 1.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

2.  A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis.

Authors:  Kazuki Terashima; Yusuke Demizu; Naoki Hashimoto; Dongcun Jin; Masayuki Mima; Osamu Fujii; Yasue Niwa; Kento Takatori; Naoto Kitajima; Sachiyo Sirakawa; Ku Yonson; Yoshio Hishikawa; Mitsuyuki Abe; Ryohei Sasaki; Kazuro Sugimura; Masao Murakami
Journal:  Radiother Oncol       Date:  2012-01-31       Impact factor: 6.280

Review 3.  Proton therapy in clinical practice: current clinical evidence.

Authors:  Michael Brada; Madelon Pijls-Johannesma; Dirk De Ruysscher
Journal:  J Clin Oncol       Date:  2007-03-10       Impact factor: 44.544

4.  Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma.

Authors:  Shohei Komatsu; Takumi Fukumoto; Yusuke Demizu; Daisuke Miyawaki; Kazuki Terashima; Ryohei Sasaki; Yuichi Hori; Yoshio Hishikawa; Yonson Ku; Masao Murakami
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

5.  Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.

Authors:  James D Murphy; Saroja Adusumilli; Kent A Griffith; Michael E Ray; Mark M Zalupski; Theodore S Lawrence; Edgar Ben-Josef
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-26       Impact factor: 7.038

6.  Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer.

Authors:  Kenta Sui; Takehiro Okabayashi; Yasuo Shima; Sojiro Morita; Jun Iwata; Tatsuaki Sumiyoshi; Yuichi Saisaka; Yasuhiro Hata; Yoshihiro Noda; Manabu Matsumoto; Akihito Nishioka; Tastuo Iiyama; Yasuhiro Shimada
Journal:  Br J Radiol       Date:  2017-06-07       Impact factor: 3.039

7.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

Authors:  Patrick J Loehrer; Yang Feng; Higinia Cardenes; Lynne Wagner; Joanna M Brell; David Cella; Patrick Flynn; Ramesh K Ramanathan; Christopher H Crane; Steven R Alberts; Al B Benson
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

8.  High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer.

Authors:  Hiromitsu Iwata; Masao Murakami; Yusuke Demizu; Daisuke Miyawaki; Kazuki Terashima; Yasue Niwa; Masayuki Mima; Takashi Akagi; Yoshio Hishikawa; Yuta Shibamoto
Journal:  Cancer       Date:  2010-05-15       Impact factor: 6.860

9.  Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.

Authors:  Makoto Shinoto; Shigeru Yamada; Kotaro Terashima; Shigeo Yasuda; Yoshiyuki Shioyama; Hiroshi Honda; Tadashi Kamada; Hirohiko Tsujii; Hiromitsu Saisho
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-12-20       Impact factor: 7.038

10.  FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.

Authors:  Mustafa Suker; Joost J Nuyttens; Bas Groot Koerkamp; Ferry A L M Eskens; Casper H J van Eijck
Journal:  J Surg Oncol       Date:  2018-09-27       Impact factor: 3.454

View more
  6 in total

1.  A Female With Synchronous Multiple Primary Malignant Tumors in the Esophagogastric Junction, Duodenum and Pancreas: Case Report and Review of the Literature.

Authors:  Yongxing Du; Yunjie Duan; Lipeng Zhang; Zongting Gu; Xiaohao Zheng; Zongze Li; Chengfeng Wang
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

Review 2.  Proton Therapy in the Management of Pancreatic Cancer.

Authors:  Jana M Kobeissi; Charles B Simone; Haibo Lin; Lara Hilal; Carla Hajj
Journal:  Cancers (Basel)       Date:  2022-06-04       Impact factor: 6.575

3.  Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study.

Authors:  Yuta Ogura; Kazuki Terashima; Yoshihide Nanno; SungChul Park; Masaki Suga; Daiki Takahashi; Yoshiro Matsuo; Nor Shazrina Sulaiman; Sunao Tokumaru; Tomoaki Okimoto; Hirochika Toyama; Takumi Fukumoto
Journal:  Radiat Oncol       Date:  2022-02-10       Impact factor: 3.481

4.  Finite Element-Based Personalized Simulation of Duodenal Hydrogel Spacer: Spacer Location Dependent Duodenal Sparing and a Decision Support System for Spacer-Enabled Pancreatic Cancer Radiation Therapy.

Authors:  Hamed Hooshangnejad; Sina Youssefian; Amol Narang; Eun Ji Shin; Avani Dholakia Rao; Sarah Han-Oh; Todd McNutt; Junghoon Lee; Chen Hu; John Wong; Kai Ding
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

5.  Laparoscopic spacer placement for bulky lymph node metastasis of cervical cancer: A case report.

Authors:  Airi Kuruma; Michiko Kodama; Ai Miyoshi; Fumiaki Isohashi; Aska Toda; Satoshi Nakagawa; Yasuto Kinose; Tsuyoshi Takiuchi; Eiji Kobayashi; Kae Hashimoto; Yutaka Ueda; Kenjiro Sawada; Tadashi Kimura
Journal:  Gynecol Oncol Rep       Date:  2022-09-27

6.  Demonstrating the benefits of corrective intraoperative feedback in improving the quality of duodenal hydrogel spacer placement.

Authors:  Hamed Hooshangnejad; Sarah Han-Oh; Eun Ji Shin; Amol Narang; Avani Dholakia Rao; Junghoon Lee; Todd McNutt; Chen Hu; John Wong; Kai Ding
Journal:  Med Phys       Date:  2022-04-18       Impact factor: 4.506

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.